Futures are down again, but several stocks are making big moves higher.... January 03, 2024 | [Read Online]( Chris Dinello
January 03, 2024 Good Morning! It's Chris from Elite Trade Club, here to give you this morning's premarket trading news. Let's get ready to trade! Markets ð U.S benchmarks struggled in their first day of trading in the New Year. The Dow managed a small gain, while a rout in tech stocks drove the Nasdaq to a steep sell off. - S&P 500 [-0.5%] - Dow [<0.1%] - Nasdaq [-1.6%] - Russell 2K [-0.7%] Futures are down again in early premarket trading. S&P 500 contracts are showing a 0.4% decline. [These AI Stocks Could Skyrocket in 2024!]( With AI's predicted surge to $2 trillion in just 7 years, now might be the prime time to invest. Those who master AI could become the worldâs first millionaires, according to tech mogul Mark Cuban. These picks for the 5 best AI stocks could get you in the door while thereâs still time to get in near the ground floor. [Access the Full Report on the Next Page]( Premarket Highlights ð ð¨ âBig Shortâ Eisman Says Sentiment Too Bullish Steve Eisman, famed for his role in "The Big Short," expresses caution over the current bullish sentiment on Wall Street. Despite his long-term optimism, Eisman, a senior portfolio manager at Neuberger Berman, voices concerns in a CNBC "Fast Money" interview. His worries center around high expectations, particularly regarding the "Magnificent Seven" tech stocks and the anticipation of multiple interest rate cuts in 2024. ð Market's Mixed Opening to the YearÂ
The year's first trading day saw mixed results: - Nasdaq's Decline: The tech-heavy index dropped 1.6%. - S&P 500's Fall: A slight decrease of 0.6%. - Dow's Minimal Gain: A contrast to the overall trend with a slight increase. These movements follow a strong 2023, where Nasdaq rallied 43%, the S&P 500 soared 24%, and the Dow climbed nearly 14%. ð¤ Eisman's Warnings Amidst BullishnessÂ
Eisman reflects on the market's journey, climbing a "wall of worry" throughout the previous year. He highlights a general bullish consensus but cautions that any disappointments could destabilize the market. Eisman points out that fewer rate hikes than the market anticipates could act as a negative short-term catalyst. ðï¸ Federal Reserve's Rate Cut Expectations
Eisman draws parallels with former Fed Chief Paul Volcker's experiences in the 1980s, suggesting the current Fed might adopt a more cautious stance towards rate cuts. He anticipates only one rate cut unless a recession occurs, believing the Fed doesn't need to be aggressive in trimming rates if the economy avoids recession. Eisman's analysis reminds investors of the delicate balance between optimism and the realities of economic and monetary policies, and, given his penchant for accurate contrarian predictions, you should probably take his warning seriously. What to Watch Today ð Tech Stocks
One of December's hottest trades is quickly cooling off in the New Year. The Nasdaq suffered its biggest decline since October yesterday, and futures are down again in the premarket. Has the tech rally peaked? Doubtful, but it could be the beginning of a pullback. The S&P 500 and Nasdaq are still sitting relatively close to new record highs, but the indexes will need the tech sector to perform to break through increasingly stiff resistance around their all-time highs. Featured Earnings ð² - UniFirst [UNF] ... AM - Cal-Maine Foods [CALM] ... PM - Simulations Plus [SLP] ... PM - Resources Connection [RGP] ... PM Economy ð - U.S. job openings [Nov] ... 10:00a - ISM manufacturing [Dec] ... 10:00a - Auto sales [Dec] ... TBA Running Hot ð¥ Gainers - Ucommune Intl. [UK] >> +53.0% - Sigma Labs [SASI] >> +65.5% - First Wave Bio [FWBI] >> +64.9% Decliners - Flex [FLEX] >> (25.6%) - Hallmark [HALL] >> (20.8%) - Nemaura Medical [NMRD] >> (25.1%) Dyne Therapeutics [DYN] - Last Close: $13.06 Upbeat data from trials of DYNE-101 in mytonic dystrophy type 1 and DYNE-251 in Duchenne muscular dystrophy patients is boosting this micro-cap biotech. Dyne said trails of DYNE-101 and D-251 helped the company refine dosing, and clinicians observed improved muscle delivery and other promising developments. Dyneâs CEO, Joshua Brumm: "This positions us to optimize dose and dose regimen in both trials with the goal of initiating registrational cohorts as we end 2024." DYN is a top mover with a 44.3% gain on more than 2 million shares traded. My Take: DYN has been gaining steadily over the past few weeks. Shares are up 64.5% over the past 3 months. Todayâs catalyst could help it extend its hot streak even further. NextImmune [NEXI] - Last Close: $2.375 Todayâs hottest premarket stock is this clinical-stage biotech stock with a float of just $2.51 million, as of Tuesdayâs close. Shares are rocketing higher despite no obvious catalyst. A quick survey of social media seems to indicate the stock is being targeted by day traders. The âWall Street Betsâ style buying raid seeks to take advantage of the stockâs small float and elevated short rate, which measured in at 4.61% on 12/15. NEXI is todayâs top premarket mover with a 137.9% gain on nearly 5 million shares traded so far. My Take: NEXI is getting a big boost from the move but I donât think it will last. Several highly visible influencers are advising followers to dump this stock and move into $UK, which has an even smaller float. ABVC BioPharma [ABVC] - Last Close: $1.20 This tiny biotech and its BioLite subsidiary has received 46 million shares of AiBtl BioPharma in the first milestone payment of a global licensing deal. Under the terms of the deal, the privately-held companyâs shares were valued at roughly $10 apiece, bringing the paymentâs total value to $460 million. ABVC Bio said it also expects to receive additional milestones under the agreement, including $7 million cash and 5% royalties, up to $200 million. ABVC is a top performer this morning with a 78.3% gain on 13 million shares traded in the premarket. My Take: ABVC has been in a moderately positive trend since early December, and this catalyst could help it break out of its trading ranch. Watch for resistance at the $2 mark. Trinity Place Holdings [TNPH] - Last Close: $0.1142 This struggling real estate firm is getting a boost today after one of its lenders granted it some much-needed relief on its debt. According to a late Tuesday 8-K filing, Trinityâs mortgage lender agreed to extend forbearance on the loan until January 31st. The extensions could give the company some much needed cash flow flexibility that will allow it to better serve its debts and maintain vital operations. TNPH is up 94.1% on 29 million shares traded. My Take: This is a huge move, but I am bearish on TNPH. Itâs chart is very ugly, and I think its ride on the struggle bus is just getting started. That's it for today! Thanks for reading, and good luck out there! Best Regards, â Chris D.
Elite Trade Club Join Elite Growth Stocks now for INSTANT-ACCESS to our highest-rated research report. [Get Instant Access Now]( Text ELITE to 47121 or [click here](Â to get our alerts on your mobile device, and never miss another fast-moving stock! P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP. [Sign up for SMS]( [tw]( [ig]( [yt]( [tk]( *Standard message/carrier rates may apply. Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website, which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside these emails. [Privacy Policy]( | [Terms of Service]( Update your email preferences or unsubscribe [here]( © 2024 Elite Trade Media LLC 1969 Alafaya Tr., Suite #247
Orlando, Florida 32828, United States of America